Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
All content for Medicine Matters: The Springer Medicine Podcast is the property of Editorial office Springer Medicine and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
We talk to Prof. Messoud Ashina about PACAP signaling and why targeting it might be the next big breakthrough for sustained migraine control.
Medicine Matters: The Springer Medicine Podcast
Medicine Matters is a pan-specialty podcast for doctors, that discusses the most exciting, controversial, and practice-changing topics across medical practice as a whole. In our episodes, we’ll be talking to leading clinical experts, to researchers and funding institutes, and to industry partners about the well-known and perhaps the lesser-known issues affecting doctors in their clinics. We’ll be looking at everything from new drug approvals to social issues affecting medicine, and we’ll be challenging some of the status quo along the way.
